Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2019
Reporting Period: Quarter ended June 30, 2019
Context: The filing announces preliminary unaudited net sales for the company's product UDENYCA®.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the preliminary unaudited net sales figures for UDENYCA® for the quarter ended June 30, 2019, but the specific dollar amounts are not included in the provided text.
Material Changes
No comparative financial data or material changes versus prior periods are detailed in the provided text. The filing serves solely as a notification of the issuance of a press release regarding preliminary sales results.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on July 8, 2019, regarding preliminary sales. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text beyond the standard legal disclaimer regarding the status of the press release information.
Investor Verification Checklist
- Verify the specific preliminary unaudited net sales figures for UDENYCA® by reviewing the attached press release (Exhibit 99.1), as these numbers are absent from the main filing text.
- Confirm the final audited financial results for the quarter ended June 30, 2019, in the subsequent Form 10-Q filing.
- Review the full text of the press release for any additional commentary on market trends or operational updates not captured in this summary.